A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.
Inclusion Criteria:
Exclusion Criteria:
Salt Lake City, Utah 84112, United States
Seattle, Washington 98122, United States
Praha 1 - Nove Mesto, Czech Republic 110 00, Czechia
Praha 1- Nove Mesto, 110 00, Czechia
Mérida, Yucatán 97130, Mexico
Bialystok, 15-002, Poland
Elblag, 82-300, Poland
Elblag, 82-300, Poland
Grodzisk Mazowiecki, 05-825, Poland
Torun, 87-100, Poland
Petrozavodsk, Karelia Republic 185019, Russia
Novosibirsk, 630099, Russia
Yaroslavl, 150003, Russia
Goodmayes, Essex IG3 8YB, United Kingdom
Romford, Essex RM7 0AG, United Kingdom